Author: [email protected]

Instacart Founder Exits With $1.1 Billion Fortune After IPO

Posted on by [email protected]

Apoorva Mehta’s path to becoming a billionaire was paved with determination and grit. The 37-year-old founder of grocery delivery app Instacart debuted his company on the public market this week, earning a personal net worth of $1.1 billion.

Mehta’s road to success was not straightforward. After quitting his job as a supply chain engineer at Amazon in 2010, Mehta attempted to launch over 20 startups in San Francisco, all of which failed. “I wanted to become an entrepreneur. I didn’t know what my idea was going to be,” Mehta told CNBC.

Undeterred by his string of failures, Mehta found inspiration from his own empty refrigerator and launched Instacart in 2012 to disrupt the grocery delivery industry. Instacart struggled at first, with Mehta even missing Y Combinator’s application deadline. But he managed to impress the famed accelerator’s partners by personally delivering beer to their office using his new app. With Y Combinator’s backing and $2.3 million in early funding, Instacart began spreading beyond San Francisco.

In just over a decade, Mehta has grown Instacart into a grocery delivery behemoth operating in over 14,000 cities across North America. The company has facilitated the delivery of over 900 million grocery orders and 20 billion items since its founding. Instacart now delivers groceries from over 80,000 stores, including major chains like Kroger, Costco, and Wegmans.

With Instacart’s successful IPO and $8.8 billion valuation, Mehta is transitioning from his role as executive chairman. His 11-year journey founding and leading Instacart has earned him billionaire status, proving that persistence and vision can turn startup failures into phenomenal success.

Mehta’s determination to solve a personal need despite multiple failed attempts speaks to his perseverance and self-belief. “Being an entrepreneur is about solving problems,” Mehta told Forbes India. “If you are solving problems, you are doing something meaningful.”

This tireless problem-solving ethic kept Mehta persevering through over 20 doomed startups before finding his billion-dollar idea. “I wanted to build something that really moved the needle,” Mehta told Entrepreneur. “Part of the reason I kept trying was because I wasn’t succeeding.”

Now valued at nearly $9 billion, Instacart succeeded in moving the needle for online grocery delivery in a massive way. “I’m most excited about the impact we can have on the grocery industry,” Mehta told Forbes of his goals looking forward.

As Mehta departs his executive chairman role, his grocery delivery empire promises to change how people access fresh food for years to come. Under new CEO Fidji Simo, formally of Facebook, Instacart is poised for continued innovation and growth.

Mehta’s journey underscores how entrepreneurs should not measure success purely in financial terms. “It’s about solving problems, inventing things and making an impact – not for the sake of making money but because it’s a challenge,” Mehta told Entrepreneur India. For him, impact and problem solving are the true markers of success.

After over 20 failures, Mehta never gave up on his goal of building something meaningful. His unflagging determination and vision turned a simple grocery delivery app into a multibillion-dollar public company. Mehta’s inspiring rise from failed startups to billionaire success shows how persistence and grit can overcome early stumbles to eventually change an entire industry.

An Exclusive In-Person Event for Channelchekers: NobleCon19, December 3-5, Boca Raton, Florida

Posted on by [email protected]

Noblecon19 is Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference. This year, and for the first time, it will be held at Florida Atlantic University College of Business, Executive Education complex in Boca Raton, Florida. If a school environment comes to mind – wooden tables and hard chairs – you’re in for a huge surprise. This spectacular new 52,000 square foot building features the most technologically advanced presentation rooms on the North American Conference circuit with massive screens and tiered seating, all wired for worldwide broadcast. Oh, and the chairs are ergonomic memory foam.

Enough about the facilities (except to mention there are 800 free covered parking spots), it’s what will go on inside that is making NobleCon19 among the most anticipated events in South Florida this winter. Over 200 public company executive guest speakers (CEO, CFO, COO, that level), The 2023 NCAA Men’s Basketball Coach of the Year, Dusty May, on motivational team building. “The World is Hot” panel of experts covering everything from the global economy to the daunting influence of AI. And the 43rd President of the United States, George W. Bush. Only 46 people have ascended to that position, so that’s about as exclusive as it gets.

Let’s go back to those public company executives. The true stars of the show. Emerging growth companies are synonymous with innovation. They represent breakthroughs in science, technology, and medicine. Even though that breakthrough may be right around the corner, these are lesser known companies, so it’s a hands-on way to explore and discover what the future may hold, and you’re hearing it from the c-suites of the organizations. And if you’re looking for investments with exponential growth opportunity, NobleCon will certainly help begin your due diligence. If you’re looking for the next apple, this truly is your orchard.

The agenda offers a wide range of ways to meet these executives. Each company will have a formal presentation, an informal breakout, and one-on-one meetings arranged with qualified investors. The corridors will be filled with them so a little badge-watching can lead to some great dialogue. And then there’s “The After.” It’s a networking event (party) the evening after the first day of meetings. Noble has become known for The After, perhaps even legendary. This year it’s at the Privaira Aviation hangar at the Boca Raton Airport. The theme is a throwback to 1923 – It’s also the 19th NobleCon in ‘23. Here’s the billing for the event: “Mingle with munchies, music, magic, motors, and high-flying antics – a nostalgic extravaganza.“ Noble believes that the best bits of business are done in these more casual, fun environments, so to make sure that they are very well attended, they go, as they say, all out.

NobleCon is open for anyone to attend. So who should attend? Besides the obvious – institutional investors, brokers, equity analysts, RIAs, family offices – simply, anyone who has a love for business and wants to meet and mesh with the leaders of these emerging companies. The companies themselves help subsidize the lofty cost of hosting an event of this size and caliber, so the cost to attend all events is only $399. And until October 15, if you are a registered guest of Channelchek, (here’s the real exclusive part) it’s less than half at $149! This offer is limited to the first 250 attendees. To put that in perspective, a ticket for the best seat in the house for the George W. Bush fireside chat alone (moderated by Noble’s Director of Research, Michael Kupinski) is $350. If you’re looking for the ultimate adventure in capitalism, this is it!

NobleCon19 at Florida Atlantic University, College of Business, Executive Education

December 3-5, 2023, Boca Raton, FL | www.nobleCon19.com

INVESTORS REGISTER HERE   
ENTER DISCOUNT CODE: CCMEMBERDISC

IF YOU REPRESENT A PUBLIC COMPANY AND WOULD LIKE TO BE CONSIDERED AS A PRESENTER AT NOBLECON19 CLICK HERE

Please note that lawyers, accountants, corporate consultants, investor relations, and other service providers do not qualify for the Channelchek discount.

NobleCon19 Sponsors

Learn More: Seeking Alpha  |  Privaira  |  AON  |  The Money Channel

Learn More: The Nuvo Group  |  FAU  |  Boca Raton  |  Investor Brand Network  |  SLS
Harter Secrest & Emery  |  Marcum  |  GreenbergTraurig  |  Lowenstein Sandler  |  StoneX
Dickinson Wright

Learn More: CFA Society South Florida  |  Palm Beach Hedge Fund Association 
 Boca Magazine | Delray Magazine | South Florida Stock & Bond Club
Nasdaq | Miami Finance Forum | Nelson Mullins

DoorDash Ditches NYSE for Nasdaq in Major Stock Exchange Switch

Posted on by [email protected]

Food delivery app DoorDash announced it will transfer its stock exchange listing from the New York Stock Exchange to the Nasdaq. The company will begin trading on the Nasdaq Global Select Market under the ticker ‘DASH’ starting September 27, 2023.

This represents a high-profile switch that exemplifies the fierce competition between the NYSE and Nasdaq to attract Silicon Valley tech listings. It also reflects shifting sentiments around brand associations and target investor bases.

DoorDash first went public on the NYSE in December 2020 at a valuation of nearly $60 billion. At the time, the NYSE provided the prestige and validation desired by the promising young startup.

However, DoorDash has since grown into an industry titan boasting a market cap of over $30 billion. As a maturing technology company, Nasdaq’s brand image and investor mix provide better positioning.

Tony Xu, co-founder and CEO of DoorDash, emphasized the benefits of the Nasdaq in the company’s announcement. “We believe DoorDash will benefit from Nasdaq’s track record of being at the forefront of technology and progress,” he said.

Nasdaq has built a reputation as the go-to exchange for Silicon Valley tech firms and growth stocks. Big name residents include Apple, Microsoft, Amazon, Tesla, Alphabet, and Facebook parent company Meta.

The exchange is also home to leading next-gen companies like Zoom, DocuSign, Crowdstrike, Datadog, and Snowflake. This creates an environment tailor-made for high-growth tech outfits.

Meanwhile, the NYSE leans toward stalwart blue chip companies including Coca Cola, Walmart, Visa, Walt Disney, McDonald’s, and JPMorgan Chase. The historic exchange tends to attract mature businesses and financial institutions.

Another factor likely influencing DoorDash is the investor makeup across the competing exchanges. Nasdaq generally appeals more to growth-oriented funds and active traders. The NYSE caters slightly more to institutional investors like pension funds, endowments, and passive index funds.

DoorDash’s switch follows ride sharing pioneer Lyft’s jump from Nasdaq to the NYSE exactly one year ago. Like DoorDash, Lyft desired a brand halo as it evolved past its early startup days.

“It’s a signal of us being mature, of us continuing to build a lasting company,” said Lyft co-founder John Zimmer at the time of the company’s NYSE listing.

Jared Carmel, managing partner at Manhattan Venture Partners, believes these exchange transfers reflect the “changing identities of the companies.”

As startups develop into multi-billion dollar giants, they evaluate whether their founding exchange still aligns with their needs and desired perceptions. Brand association and shareholder registration are becoming as important as operational capabilities for listings.

High-flying growth stocks like DoorDash also consider indexes, as the Nasdaq 100 often provides greater visibility and buying power from passive funds tracking the benchmark. Prominent inclusion in those indexes requires trading on Nasdaq.

Whether mature blue chips or emerging Silicon Valley darlings, the rivalry between Nasdaq and NYSE will continue heating up as each exchange vies to attract and retain brand name public companies. With lucrative listing fees on the line, exchanges will evolve branding, services, and capabilities to better cater to their target customers.

The DoorDash switcheroo exemplifies the changing perspectives and motivations influencing exchange selection. As companies lifecycles and personas transform, they reevaluate decisions made during those frenetic early IPO days.

Chesapeake Utilities to Acquire Florida City Gas in $923 Million Deal

Posted on by [email protected]

Chesapeake Utilities Corporation announced Monday that it has entered into an agreement to acquire Florida City Gas (FCG) from NextEra Energy for $923 million in cash. The acquisition will significantly expand Chesapeake’s presence in the growing Florida energy market.

FCG is the eighth largest natural gas local distribution company in Florida, serving around 120,000 residential and commercial customers across eight counties. Its infrastructure includes approximately 3,800 miles of distribution pipelines and 80 miles of transmission pipelines.

According to Jeff Householder, President and CEO of Chesapeake Utilities, natural gas demand in Florida continues to rise as consumers and businesses seek reliable, domestic, and affordable energy. With this acquisition, Chesapeake aims to capitalize on the robust growth opportunities across the state.

“This acquisition will more than double our natural gas business in Florida, one of the fastest growing states in the nation,” said Householder. “We see significant potential to continue pursuing long-term earnings growth.”

The deal is expected to close by the end of the fourth quarter of 2023, subject to regulatory approvals. Once completed, FCG will become a wholly owned subsidiary of Chesapeake Utilities.

Chesapeake has a strong track record of successfully integrating acquisitions to drive growth, as seen in its purchase of Florida Public Utilities in 2009. The company believes it can optimize FCG’s operations and execute on additional investments in gas distribution, transmission, and other energy platforms.

To finance the deal, Chesapeake plans to utilize a mix of equity and long-term debt to maintain balance sheet strength. The company has also obtained committed financing from Barclays.

Chesapeake has extended its earnings guidance through 2028 based on the increased scale and opportunities from FCG. It expects earnings per share growth of approximately 8% through 2028. The company also increased its 5-year capital expenditure guidance to $1.5-$1.8 billion.

The FCG acquisition demonstrates Chesapeake’s strategy of consolidating natural gas assets and positioning itself for growth in key geographies. As energy markets evolve, strategic deals allow companies like Chesapeake to enhance their competitive position.

Mortgage Rates Hit 23-Year High

Posted on by [email protected]

Mortgage rates crossed the 7% threshold this past week, as the 30-year fixed rate hit 7.31% according to Freddie Mac data. This marks the highest level for mortgage rates since late 2000.

The implications extend far beyond the housing market alone. The sharp rise in rates stands to impact the stock market, economic growth, and investor sentiment through various channels.

For stock investors, higher mortgage rates pose risks of slower economic growth and falling profits for rate-sensitive sectors. Housing is a major component of GDP, so a pullback in home sales and construction activity would diminish economic output.

Slower home sales also mean less revenue for homebuilders, real estate brokers, mortgage lenders, and home furnishing retailers. With housing accounting for 15-18% of economic activity, associated industries make up a sizable chunk of the stock market.

A housing slowdown would likely hit sectors such as homebuilders, building materials, home improvement retailers, and home furnishing companies the hardest. Financial stocks could also face challenges as mortgage origination and refinancing drop off.

Broader economic weakness resulting from reduced consumer spending power would likely spillover to impact earnings across a wide swath of companies and market sectors. Investors may rotate to more defensive stocks if growth concerns escalate.

Higher rates also signal tightening financial conditions, which historically leads to increased stock market volatility and investor unease. Between inflation cutting into incomes and higher debt servicing costs, consumers have less discretionary income to sustain spending.

Reduced consumer spending has a knock-on effect of slowing economic growth. If rate hikes intended to fight inflation go too far, it raises the specter of an economic contraction or recession down the line.

For bond investors, rising rates eat into prices of existing fixed income securities. Bonds become less attractive compared to newly issued debt paying higher yields. Investors may need to explore options like floating rate bonds and shorter duration to mitigate rate impacts.

Rate-sensitive assets that did well in recent years as rates fell may come under pressure. Real estate, utilities, long-duration bonds, and growth stocks with high valuations are more negatively affected by rising rate environments.

Meanwhile, cash becomes comparatively more attractive as yields on savings accounts and money market funds tick higher. Investors may turn to cash while awaiting clarity on inflation and rates.

The Fed has emphasized its commitment to bringing inflation down even as growth takes a hit. That points to further rate hikes ahead, meaning mortgage rates likely have room to climb higher still.

Whether the Fed can orchestrate a soft landing remains to be seen. But until rate hikes moderate, investors should brace for market volatility and economic uncertainty.

Rising mortgage rates provide yet another reason for investors to ensure their portfolios are properly diversified. Maintaining some allocation to defensive stocks and income plays can help smooth out risk during periods of higher volatility.

While outlooks call for slower growth, staying invested with a long-term perspective is typically better than market timing. Patience and prudent risk management will be virtues for investors in navigating markets in the year ahead.

Uranium Prices Hit 12-Year High on Rising Demand

Posted on by [email protected]

Uranium prices have hit their highest level in 12 years, reaching around $70 per pound in recent trading. This marks a major rally for the nuclear fuel, as prices were languishing below $30 per pound just a couple years ago. The uranium market has seen renewed interest from investors and utilities lately, driving the huge spike in prices.

Image Credit: Trading Economics

Uranium is a key material used in nuclear power generation. It is the fuel inside nuclear reactors that undergoes fission to release massive amounts of energy. Uranium is mined from the ground, then processed and enriched before being fabricated into fuel rods for insertion into reactors. Nuclear power plants require a steady supply of uranium fuel to continue operating.

There are several factors behind the big jump in uranium prices recently. A major one is increased demand, as more nuclear reactors are being built around the world. China in particular has been rapidly expanding its nuclear energy capabilities. More reactors coming online globally means more demand for uranium fuel. Supply has also been constrained lately, with pandemic-related disruptions slowing some uranium mining operations. This demand/supply imbalance has helped drive uranium prices markedly higher.

The surge in uranium prices is great news for uranium mining companies and producers. Major players in the global uranium market like Cameco, Kazatomprom, and Energy Fuels stand to benefit greatly from elevated prices. Their profitability increases significantly when uranium prices rise. These companies have seen their stock prices jump this year in tandem with the uranium price rally. Many uranium stocks are up 50% or more year-to-date.

According to Noble Capital Markets Senior Research Analyst Michael Heim, “There has been an imbalance between domestic uranium supply and demand over the last 15 years as consumers (electric utilities) purchased cheap uranium from foreign nations such as Kazakhstan under short-term contracts. Domestic producers curtailed production with spot prices below production costs. With prices now near $70 per pound and electric utilities increasingly willing to sign longer-term contracts, domestic uranium companies like Energy Fuels are able to restart operations.”

Take a moment to take a look at Energy Fuels Inc., a leading U.S.-based uranium mining company, supplying major nuclear utilites.

The hot uranium market also has implications for the broader stock market. The S&P 500 energy sector has been one of the top performing segments this year. Rising uranium prices provide an added catalyst, as nuclear energy becomes relatively more cost competitive. Utility companies running nuclear power plants also benefit from lower relative fuel costs. This can enhance their profitability and lead to upside in the utilities sector.

Overall, the big rebound in uranium prices reflects growing global demand for nuclear power. New reactor projects and increased focus on energy security are driving uranium back to multi-year highs. This should provide a boost to uranium producers and related stocks going forward. Nuclear power appears poised for increased utilization in the years ahead, which points to a strong fundamental outlook for uranium prices. As long as demand keeps rising faster than supply, uranium seems likely to maintain its bull run.

Alfasigma Makes Big Bet on Liver Disease With $1.25 Billion Intercept Buyout

Posted on by [email protected]

Italian pharma Alfasigma is expanding its gastroenterology portfolio in a major way with the proposed $1.25 billion acquisition of Intercept Pharmaceuticals. The all-cash deal provides Alfasigma with Intercept’s leading drug Ocaliva and a strengthened pipeline in progressive liver diseases.

Alfasigma will pay $19 per share to acquire Intercept, representing an 82% premium over Intercept’s share price before the deal announcement. The purchase price reflects a big bet on Ocaliva’s growth prospects and Intercept’s broader capabilities in rare liver conditions.

Ocaliva is the key asset Alfasigma gains from the deal. It’s the only FDA approved second-line treatment for primary biliary cholangitis (PBC), a progressive autoimmune disorder that damages the bile ducts in the liver. Ocaliva hit $152 million in sales over the first half of 2023 alone, underscoring its rapid growth trajectory.

Beyond Ocaliva, Alfasigma also adds Intercept’s emerging pipeline of novel therapies for PBC and other liver diseases. The crown jewel is a promising fixed-dose combination regimen that could transform the PBC treatment paradigm.

Take a look at Noble Capital Markets Senior Life Sciences Analyst Robert LeBoyer’s coverage universe.

The deal dramatically expands Alfasigma’s presence in the high-value U.S. pharma market. Previously focused primarily on the Italian market, the Intercept acquisition gives Alfasigma an anchor asset and commercial team in the U.S.

Strategically, the move aligns with Alfasigma’s vision to build up its gastroenterology and hepatology business. CEO Francesco Balestrieri highlighted Intercept’s compelling strategic fit with Alfasigma’s focus in these therapeutic areas.

Expect Alfasigma to invest heavily to maximize Ocaliva’s potential. The company sees major commercial expansion opportunities to extend Ocaliva’s reach across PBC patient populations. Alfasigma also gains Intercept’s seasoned specialty sales force to drive prescription growth.

With Intercept operating as a wholly-owned subsidiary once the buyout closes, Alfasigma is well-positioned to become a global force in progressive liver diseases. The deal enhances Alfasigma’s standing as an emerging player in the U.S. pharma market.

Look for Alfasigma to continue seeking acquisition targets to accelerate its growth. The company has the financial firepower to pursue additional deals that build up its portfolio. If the Intercept acquisition is any indication, Alfasigma has appetite for bold, transformative M&A.

The proposed buyout still requires regulatory and shareholder approval. But with a massive 82% premium offered, Intercept shareholders are likely to approve the $19 per share deal price. Expect Alfasigma to move rapidly to complete the acquisition by the end of 2023.

Soleno Therapeutics Stock Skyrockets 505% on Hunger Pill Promise

Posted on by [email protected]

Shares of Soleno Therapeutics (SLNO) catapulted an astonishing 505% higher last week after positive late-stage clinical results for the company’s experimental obesity and hunger control pill. The massive stock surge demonstrates investor enthusiasm around Soleno’s DCCR pill as a potential new medicine for Prader-Willi syndrome (PWS).

DCCR aims to treat hyperphagia, or abnormally increased hunger and food drive, in patients with PWS. The rare genetic disorder can lead to excessive eating, obesity, and other complications. Soleno’s pill showed promising ability to control hunger signals in PWS patients during a 4-month placebo-controlled withdrawal study.

The trial enrolled 77 PWS patients who had been taking DCCR for 2-4 years. Half the participants continued their DCCR regimen, while the other half were switched to placebo. After just one month, the placebo group showed a rapid return of hyperphagia symptoms. On a 9-point clinical scale, their hunger scores increased by a significant 5 points on average.

In contrast, PWS patients who remained on DCCR maintained stable, controlled hunger levels throughout the 4-month trial. The results provide strong evidence that DCCR specifically curbs abnormal hunger drive in PWS, rather than just having a placebo effect.

Beyond hunger control, PWS patients taking placebo also showed worsening in overall PWS symptoms and severity. No new safety issues emerged during the 4 months on placebo, indicating the hunger control benefits of DCCR remained after stopping treatment.

Armed with the successful phase 3 results, Soleno now plans to submit a New Drug Application for DCCR to the FDA in mid-2024. The company is seeking an initial approval in PWS, which would make DCCR the first ever pharmacotherapy for hyperphagia associated with the condition.

The FDA previously designated DCCR an Orphan Drug for treating PWS. This status provides incentives to develop medicines for rare diseases, since PWS affects only about 15,000-16,000 individuals in the U.S. The new trial results could support approval based on the FDA’s prior guidance.

If greenlighted, analysts project DCCR peak sales could reach $500 million – $1 billion annually. The pill would provide a novel, non-surgical therapeutic option to manage hyperphagia and obesity in PWS. DCCR’s unique clinical benefits could command premium pricing above $100,000 per patient annually.

Soleno still has work ahead to realize commercialization, including securing FDA approval and payer coverage. But the company now has a de-risked late stage asset and clear regulatory path forward. The 505% share price spike last week reflects renewed investor confidence in DCCR’s commercial potential.

Despite the rally, Soleno still trades 70% below its 2018 highs. The stock has suffered from past clinical setbacks that stoked skepticism around DCCR. But with a successful phase 3 trial now completed, the tide may be turning.

Soleno could seek to expand DCCR’s use into additional patient populations with uncontrolled hunger and obesity issues beyond PWS. The pill works by modulating metabolic pathways that drive hyperphagia symptoms.

While gains may moderate going forward, last week’s huge rally kicks off a new chapter for Soleno stock. Look for the company to shift focus from pivotal trial execution to commercial planning. Investors cheered the pivotal data, signaling confidence in DCCR’s prospects. Soleno still has work left to turn its hunger-controlling pill into an FDA-approved medicine, but the 505% surge shows just how much upside investors anticipate.

Release – Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘POWER’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric Obesity

Senate Poised to Advance Landmark Marijuana Banking Reform

Posted on by [email protected]

A long-awaited bill that could unlock banking access for the marijuana industry is slated for a historic Senate vote this week. The Secure and Fair Enforcement (SAFE) Banking Act aims to allow financial institutions to work with state-legal cannabis businesses without facing federal punishment.

The Senate Banking Committee will vote Wednesday on whether to advance the bill to the full chamber floor. If approved as expected, it would mark the first time the SAFE Banking Act has ever cleared the Senate.

The bill takes aim at a major hurdle facing the growing marijuana industry – lack of access to basic banking and financial services. Currently, most banks and credit unions refuse to handle cannabis company accounts due to marijuana’s federal prohibition as an illegal Schedule 1 drug.

That forces many marijuana firms to operate entirely in cash, creating public safety issues and barriers to business expansion. The SAFE Banking Act provides legal cover for financial institutions to work with state-approved cannabis companies.

The bipartisan bill is sponsored by Senators from both parties representing states with legal marijuana markets. It previously passed the Democrat-led House seven times, but stalled each time in the Senate. Wednesday’s vote would break the logjam.

If enacted into law, industry analysts project the SAFE Banking Act could catalyze billions in new capital investment into the marijuana sector. Cannabis companies would gain access to basic banking and credit services to help fuel their growth.

Take a moment to look at Schwazze, a leading vertically integrated cannabis holding company with a portfolio spanning cultivation, extraction, infused-product manufacturing, dispensary operations, consulting, and a nutrient line.

However, the bill still faces an uphill path to final passage. It must clear both the full Senate and the Republican-controlled House, where some members remain opposed to marijuana reform. But the historic committee vote marks a major milestone after years of lobbying from cannabis businesses.

The SAFE Banking Act underscores marijuana’s transition from the black market to a legitimate, multibillion-dollar American industry. Medical and recreational cannabis is now legal in 39 states, but lack of banking access continues to hinder the sector’s expansion and safety.

Wednesday’s vote is a significant step toward providing financial access and security for state-compliant marijuana companies. Passage would enable the cannabis industry to further emerge from the shadows.

President Biden Makes History by Joining UAW Picket Line

Posted on by [email protected]

On Tuesday, September 26, 2023, President Joe Biden made history by joining striking United Auto Workers (UAW) members on the picket line in Wayne County, Michigan. It was the first time a sitting president had ever joined an ongoing strike.

Biden’s visit came as the UAW was in its 12th day of a strike against General Motors, Ford, and Stellantis, demanding better wages, benefits, and job security. The strike had caused significant disruptions to the auto industry and had put thousands of workers out of work.

Despite the risks, Biden was determined to show his support for the UAW and for working families. He arrived at the picket line early in the morning and was greeted by cheers and applause from the strikers.

“It’s an honor to be here with you today,” Biden said to the strikers. “You are fighting for the middle class. You are fighting for the soul of this nation.”

Biden went on to praise the UAW for its long history of fighting for the rights of workers and their families. He also pledged his support for the union and said that he would continue to work to create an economy that works for everyone.

“I want to be clear: I stand with the UAW,” Biden said. “I will always stand with workers who are fighting for a fair deal.”

Biden’s visit to the picket line was a significant show of support for the UAW and for labor unions in general. It came at a time when unions are facing increasing attacks from corporations and anti-union politicians.

Biden’s visit was also a reminder of his commitment to working families. He has repeatedly said that he will fight to create an economy that works for everyone, not just the wealthy few.

Biden’s visit to the picket line could have a number of positive consequences for the UAW and for labor unions in general.

First, it could help to raise public awareness of the strike and the union’s demands. This could put pressure on the auto companies to settle the strike on the union’s terms.

Second, Biden’s visit could help to boost morale among the strikers. It could show them that they have the support of the president and that they are not alone in their fight.

Third, Biden’s visit could help to strengthen the labor movement as a whole. It could show that unions are still a powerful force and that they can win when they stand together.

Biden’s visit to the picket line was also significant for its historical implications. It was the first time a sitting president had ever joined an ongoing strike. This sent a powerful message that the president stands with working families and that he supports the right of workers to organize and bargain collectively.

Biden’s visit to the picket line was a courageous and important act. It showed that he is a president who is not afraid to stand up for working families, even when it is politically difficult.

The UAW strike is a critical test for Biden’s presidency. If the union is able to win a fair contract, it will be a victory for working families and for the labor movement as a whole. It will also be a sign that Biden is delivering on his promise to create an economy that works for everyone.

The strike is also a test for the Biden administration’s commitment to industrial policy. Biden has repeatedly said that he wants to revitalize the American manufacturing sector. The UAW strike is an opportunity for Biden to show that he is serious about this commitment.

The Biden administration can support the UAW strike in a number of ways. First, it can put pressure on the auto companies to settle the strike on the union’s terms. Second, it can provide financial assistance to the strikers and their families. Third, it can use its regulatory authority to make it easier for workers to organize and bargain collectively.

The UAW strike is a critical moment for working families and for the labor movement. The outcome of the strike will have a major impact on the future of the American economy. Biden’s visit to the picket line was a significant show of support for the UAW and for working families. It is now up to the Biden administration to follow through on its promises and to ensure that the UAW strike is a victory for working families.

Looming Government Shutdown Tests McCarthy’s Leadership

Posted on by [email protected]

Washington braces for its first potential government shutdown under House Speaker Kevin McCarthy’s speakership as the fiscal year-end nears on September 30. The high-stakes funding clash represents an early test of McCarthy’s ability to lead a fractious Republican majority.

The face-off caps months of growing friction between McCarthy and the hardline House Freedom Caucus that helped install him as Speaker in January. To gain their votes, McCarthy pledged he would not advance spending bills without “majority of the majority” Republican backing.

That concession has now put McCarthy in a bind as the shutdown deadline approaches without a funding agreement in place. The Freedom Caucus is demanding McCarthy leverage the must-pass spending legislation to cut budgets and advance conservative policies, like defunding the FBI.

However, McCarthy knows Senate Democrats would never accept such ideological provisions. And a prolonged government shutdown could batter the fragile economy while eroding public faith in governance competence.

With only days remaining, McCarthy weighs risky options without easy solutions. Scheduling a vote on a stripped-down continuing resolution to temporarily extend current funding would break his promise to the Freedom Caucus.

Yet refusing to hold a vote risks blame for an unpopular shutdown. McCarthy also considers putting a Senate-passed funding bill to a House floor vote, prompting Freedom Caucus warnings that doing so would incite calls for his ouster.

The Speaker urgently needs to unify Republicans behind a way forward. But McCarthy must balance the Freedom Caucus’ demands against the consequences of failing to avert a shutdown.

Navigating these pressures will test McCarthy’s ability to govern a narrow 222-seat majority. It will also gauge whether he can effectively steer the party into the 2024 elections amid internal divisions.

With only 18% of Americans supporting shutdowns over policy disputes according to polls, McCarthy likely wants to avoid a disruptive funding lapse. A 2013 closure lasting 16 days is estimated to have shaved 0.2-0.6% from economic growth that quarter.

From furloughing 800,000 federal workers to suspending services, even a short shutdown could batter public trust in leadership. The military’s over 1.3 million active duty members would see pay disrupted. National Parks could close, impacting over 297 million annual visitors.

The high-risk brinkmanship highlights the difficulty McCarthy faces satisfying the party’s warring moderate and Freedom Caucus wings. Finding a solution that keeps government open while saving face with hardliners will prove a true test of McCarthy’s political dexterity.

Past shutdowns under divided government have tended to end once public pressure mounted on the blamed party. While Republicans control the House, most fault would land on them for manufacturing a crisis.

Yet McCarthy cannot disregard the Freedom Caucus, whose backing enabled his ascension to power. The days ahead will reveal whether McCarthy has the savvy to extricate the GOP from a crisis partly of its own making.

McCarthy’s handling of the funding impasse will set the tone for his entire speakership. At stake is nothing less than his ability to govern, deliver on promises, and prevent self-inflicted wounds entering 2024.

Precision Motion Company Allient Acquires Design Firm Sierramotion

Posted on by [email protected]

Allient Inc. (Nasdaq: ALNT), a designer and manufacturer of specialty motion control products, has acquired Sierramotion Inc., a private company specializing in precision motion solutions. The deal expands Allient’s capabilities in highly-engineered motion components for robotic, medical, industrial and other applications.

California-based Sierramotion brings decades of experience designing customized electro-mechanical systems. Their expertise spans rotary, linear and arc motion applications. Sierramotion provides rapid prototyping, testing and low volume manufacturing for customers across industries like semiconductor, defense and robotics.

The acquisition aligns with Allient’s strategy of adding new technologies through M&A. Sierramotion’s engineering talent and nimble product development will aid Allient’s push into integrated motion systems. Combined with Allient’s larger scale manufacturing footprint, the deal creates opportunities to commercialize Sierramotion’s innovations.

Allient sees motion control as a high-growth market driven by automation and electrification trends. Their targeted sectors include factory automation, surgical robotics, last-mile delivery, drones and electric vehicles. Allient aims to leverage acquisitions to expand capabilities across this diverse customer base.

The addition of Sierramotion also boosts Allient’s new product development capacity, speeding time-to-market. Quick turn prototyping and close customer collaboration helps Sierramotion rapidly refine motion components. Integrating these strengths with Allient’s global manufacturing creates a competitive advantage.

Founded in 2019, Sierramotion has worked previously with Allient to co-develop motion solutions. The existing relationship and complementary capabilities make for a seamless integration of the two companies per management. Expect the deal to be immediately accretive.

Allient continues executing on a well-defined acquisition strategy aimed at shareholder value creation. The company looks for targets that expand its motion technology portfolio and bring specialized engineering talent. Disciplined capital deployment and operating excellence remain priorities for the Buffalo, NY-based firm.

Sierramotion also offers entry into growing West Coast technology hubs. The acquisition provides a footprint near potential customers across tech sectors. Overall, the deal enhances Allient’s competitive positioning within precision motion control, a key focus area for the company.

Keep an eye out for new motion control products as Allient leverages Sierramotion’s unique capabilities. The merger kicks Allient’s acquisition-driven expansion into higher gear as management vows to seize opportunities and lead innovation.

Regeneron Strengthens Gene Therapy Pipeline Through Acquisition of Decibel Therapeutics

Posted on by [email protected]

Regeneron Pharmaceuticals has expanded its gene therapy programs by acquiring Decibel Therapeutics, a biotech company focused on developing treatments for hearing loss. The $1.1 billion deal provides Regeneron with three promising gene therapy candidates that use adeno-associated virus (AAV) vectors to restore hearing.

The most advanced asset is DB-OTO, an AAV-based gene therapy designed to provide long-term hearing to individuals with profound congenital hearing loss caused by otoferlin gene mutations. DB-OTO is currently being evaluated in a Phase 1/2 clinical trial known as CHORD. The gene therapy aims to deliver a functional copy of the otoferlin gene to inner ear hair cells, potentially enabling hearing restoration.

The acquisition also includes two earlier-stage gene therapies, AAV.103 and AAV.104, targeting other genetic forms of hearing loss – GJB2 and STRC respectively. Both utilize a similar AAV gene delivery approach to DB-OTO.

According to Regeneron, the addition of Decibel’s pipeline and capabilities will strengthen its genetic medicines portfolio. Gene therapy has become a major focus for Regeneron beyond its foundational expertise in antibodies. The company is exploring gene silencing, gene editing and gene therapy technologies across a range of therapeutic areas.

Take a look at Ocugen Inc., a biotechnology company focused on discovering, developing and commercializing novel gene and cell therapies and vaccines.

Hearing loss represents a new area for Regeneron, building on an existing collaboration with Decibel. Integration of Decibel’s team and experience in inner ear biology and AAV gene therapy for hearing disorders will be invaluable as Regeneron advances the acquired programs.

Gene therapy aims to address disease at its genetic root cause by introducing functional genes into cells. The goal is to durably restore protein expression and correct the downstream impacts of gene mutations. Gene therapy has shown promise for treating rare monogenic disorders like certain forms of inherited hearing loss.

Both Regeneron and Decibel have utilized AAV vectors to deliver gene therapy payloads. AAV is considered one of the most effective vehicles for gene delivery and has an established safety profile. The viruses can be engineered to target specific cell types following injection into the body.

For DB-OTO, the AAV vector carries a functional copy of the otoferlin gene. Inner ear hair cells are the targets for gene transduction. Otoferlin protein is critical for hearing signal transduction, but mutations in the encoding gene cause profound congenital deafness. Gene therapy aims to restore otoferlin expression and regain hearing function.

Regeneron’s push into gene therapy aligns with its mission of tackling serious diseases with novel technologies. Gene-based treatments have potential for one-time curative therapies. The acquisition of Decibel’s pipeline further diversifies Regeneron’s genetic medicine capabilities as it aims to help patients worldwide.